Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Journal of the American College of Cardiology
|
August 18, 2004
Altered myocardial Ca2+ cycling after left ventricular assist device support in the failing human heart
Khuram W Chaudhary, Eric I Rossman, Valentino Piacentino, et al.
Regulatory Toxicology and Pharmacology : RTP
|
April 15, 2026
Advancing Nonclinical Blood Pressure Assessment: Current Practices and Future Directions in Drug Development
Michael K Pugsley, Siddhartha Bhatt, Christer Gottfridsson, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
February 25, 2022
A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variables
Yu Fu, Hadi Taghvafard, Medhat M Said, et al.
Journal of Pharmacological and Toxicological Methods
|
July 15, 2020
Echocardiographic and hemodynamic indices of myocardial contractility simultaneously evaluated in telemetered beagle dogs: A HESI-sponsored cross-company evaluation
Eric I Rossman, Frank Cools, Jason Cordes, et al.
Journal of Pharmacological and Toxicological Methods
|
March 30, 2023
Improving the in Vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute
Hugo M Vargas, Eric I Rossman, Todd A Wisialowski, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
July 18, 2023
CardioMotion: identification of functional and structural cardiotoxic liabilities in small molecules through brightfield kinetic imaging
William Stebbeds, Kavita Raniga, David Standing, et al.
Journal of Pharmacological and Toxicological Methods
|
July 17, 2024
Assessment of corrected JT-peak (JTpc) and Tpeak-to-Tend (TpTec) as proarrhythmia biomarkers in non-human primates: Outcome from a HESI consortium
Emmanuel Boulay, Simon Authier, Theresa Bartko, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 3, 2009
The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model
Eric I Rossman, Kun Liu, Gwen A Morgan, et al.
Journal of Pharmacological and Toxicological Methods
|
April 7, 2015
The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESI-sponsored consortium
Brian D Guth, Alan Y Chiang, Jennifer Doyle, et al.
Journal of Medicinal Chemistry
|
January 30, 2009
Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation
John A Butera, Bjarne Due Larsen, James K Hennan, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Journal of the American College of Cardiology
|
August 18, 2004
Altered myocardial Ca2+ cycling after left ventricular assist device support in the failing human heart
Khuram W Chaudhary, Eric I Rossman, Valentino Piacentino, et al.
Regulatory Toxicology and Pharmacology : RTP
|
April 15, 2026
Advancing Nonclinical Blood Pressure Assessment: Current Practices and Future Directions in Drug Development
Michael K Pugsley, Siddhartha Bhatt, Christer Gottfridsson, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
February 25, 2022
A novel cardiovascular systems model to quantify drugs effects on the inter-relationship between contractility and other hemodynamic variables
Yu Fu, Hadi Taghvafard, Medhat M Said, et al.
Journal of Pharmacological and Toxicological Methods
|
July 15, 2020
Echocardiographic and hemodynamic indices of myocardial contractility simultaneously evaluated in telemetered beagle dogs: A HESI-sponsored cross-company evaluation
Eric I Rossman, Frank Cools, Jason Cordes, et al.
Journal of Pharmacological and Toxicological Methods
|
March 30, 2023
Improving the in Vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute
Hugo M Vargas, Eric I Rossman, Todd A Wisialowski, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
July 18, 2023
CardioMotion: identification of functional and structural cardiotoxic liabilities in small molecules through brightfield kinetic imaging
William Stebbeds, Kavita Raniga, David Standing, et al.
Journal of Pharmacological and Toxicological Methods
|
July 17, 2024
Assessment of corrected JT-peak (JTpc) and Tpeak-to-Tend (TpTec) as proarrhythmia biomarkers in non-human primates: Outcome from a HESI consortium
Emmanuel Boulay, Simon Authier, Theresa Bartko, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 3, 2009
The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model
Eric I Rossman, Kun Liu, Gwen A Morgan, et al.
Journal of Pharmacological and Toxicological Methods
|
April 7, 2015
The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESI-sponsored consortium
Brian D Guth, Alan Y Chiang, Jennifer Doyle, et al.
Journal of Medicinal Chemistry
|
January 30, 2009
Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation
John A Butera, Bjarne Due Larsen, James K Hennan, et al.
Page
of 3